Indication
Treatment of adult patients with previously untreated cell membrane receptor 30-positive (CD30+) Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).
Medicine details
- Medicine name:
- brentuximab vedotin (Adcetris)
- SMC ID:
- SMC2762
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 11 August 2025
- SMC meeting date:
- 01 July 2025
- Patient group submission deadline:
- 07 April 2025